Most significantly, FcRH5‐BCMA CAR‐T demonstrated improved tumour infiltration and longer survival than FcRH5 or BCMA monospecific CAR‐T cells in a subcutaneous NCI‐H929 xenograft model.63 This evidence concerns the gene TNFRSF17 and neoplasm.